NDAINJECTIONINJECTABLE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDELTRA-TBA (prednisolone tebutate) is an injectable corticosteroid approved in 1956 for anti-inflammatory and immunosuppressive indications. It is administered via injection and works by suppressing immune response and reducing inflammation across multiple tissue sites. The drug treats a range of inflammatory and autoimmune conditions requiring systemic corticosteroid therapy.
LOE Approaching
Product is in late-stage life cycle with modest competitive pressure (30/100), indicating a mature brand with shrinking team and defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities on HYDELTRA-TBA are minimal and likely limited to legacy brand maintenance and transition planning. This is not a growth assignment and would be suitable only for career professionals managing mature portfolios or preparing for product phase-out.
Brand ManagerField Sales Representative
Worked on HYDELTRA-TBA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.